As some of the users in this forum have mentioned, Imagion was featured in the “Emerging Stocks Down Under” analysis paper published by Stocks Down Under, highlighting our efforts to change the medical imaging market with our FDA designated “breakthrough device”.
We thank them for taking an interest in the work our company has been doing to develop this technology and its capabilities.
You can find the full paper here. Note: This paper is behind a pay wall, but access is available for a 30-day free trial on the website.
IBX Price at posting:
7.6¢ Sentiment: None Disclosure: Not Held
